Samarth Kulkarni, CRISPR Therapeutics CEO (Scott Eisen/AP Images for Breakthrough Properties)

CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

CRISPR Ther­a­peu­tics is mak­ing sev­er­al changes to its al­lo­gene­ic CAR-T cell ther­a­py pipeline, in­clud­ing pro­gram cuts and mov­ing in­to a new in­di­ca­tion as it awaits an FDA de­ci­sion on its Ver­tex-part­nered CRISPR-edit­ed ther­a­py exa-cel.

The Swiss com­pa­ny is ax­ing two of its orig­i­nal CAR-T pro­grams — CTX110 and CTX130 — to pri­or­i­tize two next-gen­er­a­tion can­di­dates with the po­ten­tial for im­proved clin­i­cal pro­files ac­cord­ing to pre­lim­i­nary da­ta from ear­ly tri­als. CRISPR said it will tran­si­tion pa­tients treat­ed with CTX110 and CTX130 to long-term fol­low-up pro­grams where rel­e­vant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA